Why HER2 Appears Above EGFR in Recruiting Trial Searches

HER2 Is a Common Name, Not the Official Symbol

The official human gene symbol is ERBB2, while HER2, HER-2 and HER2/neu are widely used synonyms. Clinical trial records often use the familiar protein or biomarker name because eligibility and treatment descriptions are written for clinical readers.

The index deliberately queries HER2 because it reflects common registry language. A separate ERBB2 query would not be interchangeable and could overlap heavily with the HER2 result.

HER2 Language Covers Several Biomarker States

HER2 can appear in records describing amplification, overexpression, activating mutation, HER2-positive disease or lower-expression categories used by some antibody-drug conjugate programmes. It is also used across breast, gastric, lung, colorectal and other tumour research.

That breadth can place the term in titles, eligibility criteria, intervention descriptions and exploratory analyses even when HER2 is not the sole experimental target.

EGFR Records Are Often More Molecularly Specific

EGFR programmes frequently specify a tumour setting and an exact alteration such as exon 19 deletion, L858R, exon 20 insertion, T790M or C797S. Records can also foreground the drug or disease rather than repeat EGFR in every searchable field.

This does not make the EGFR query narrow in an absolute sense; it explains why a simple term count is sensitive to how protocols are written and indexed.

What Would Test the Explanation

A stronger analysis would export matching records for HER2, ERBB2 and EGFR, deduplicate NCT identifiers, then classify where each term occurs and which tumour types, phases and interventions dominate. That record-level audit could separate naming effects from genuine programme breadth.

Until that work is done, the defensible conclusion is limited: HER2 produced more matches under this method on this date. The index cannot assign one single cause to the gap.

Key Takeaways

• ·HER2 is a widely used synonym for the official ERBB2 symbol.
• ·Registry counts are shaped by biomarker language, tumour breadth and searchable fields.
• ·The HER2–EGFR gap is a reproducible query result, not a clinical comparison.